SynthesisBMC gastroenterology2025
Effect of synbiotics on the cardiovascular risk factors in patients with non-alcoholic fatty liver: a GRADE assessed systematic review and meta-analysis.
Synthesis in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Gut Dysbiosis as a Shared Mechanism in Obesity and Hypertension: Exploring a Promising Therapeutic Avenue.Endocrinology, diabetes & metabolism · 2026Review
- Traditional Chinese medicine-based modulation of gut microbiota in coronary heart disease: probiotic synergy and translational perspectives.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSeveral studies revealed that synbiotics have been beneficial in managing non-alcoholic fatty liver disease (NAFLD), but the findings are conflicting. We aimed to assess the effect of synbiotic supplementation on cardiovascular risk factors in patients with NAFLD.
methodsA thorough literature search was conducted to identify relevant studies up to July 2024, including publications from Pubmed, Embase, Cochrane, Scopus, and the Web of Science. Standardized mean difference (SMD) was used, and data with a 95% confidence interval (CI) were presented.
resultsSixteen RCTs were included, involving NAFLD patients and synbiotic supplementation. No significant effects were found on blood pressure (SBP: SMD - 6.68, p = 0.234; DBP: SMD - 4.31, p = 0.391), anthropometric measures (weight: SMD - 0.78, p = 0.126; BMI: SMD - 0.21, p = 0.182; waist circumference: SMD - 0.53, p = 0.095), or lipid profile (triglycerides: SMD - 3.67, p = 0.266; total cholesterol: SMD - 0.61, p = 0.059; low-density lipoprotein: SMD - 3.09, p = 0.215; high-density lipoprotein: SMD 0.49, p = 0.219). Synbiotics significantly reduced CRP levels (SMD - 1.83, p = 0.019) but had no significant effect on TNF-α (SMD - 1.95, p = 0.087). Synbiotic led to a significant reduction in weight following adjustment of publication bias (SMD - 1.16, p < 0.05).
conclusionOverall, synbiotic supplementation does not significantly impact blood pressure, anthropometric indices, or lipid profile parameters in patients with NAFLD, except for a significant reduction in weight after adjusting for publication bias. Synbiotic supplementation significantly reduces CRP levels but has no effect on TNF-α.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.